HealthPlus Pharmacy Group – Business Plan
Investment-grade business plan for HealthPlus Pharmacy Group (Pty) Ltd — a ZAR 85-million Phase 1 raise to build a scalable retail pharmacy and wellness chain in South Africa, scaling to 25 stores and ZAR 510 million revenue by Year 5 at a 24–30% IRR.
Confidential Business Plan
HealthPlus Pharmacy Group
A scalable retail pharmacy and wellness chain for South Africa, built on the dispensary-led, front-shop-margin model proven by Dis-Chem and Clicks — structured as an investment-grade ZAR 85-million Phase 1 opportunity for equity investors and lending institutions.
South African pharmacy retail is a large, defensive market in which Dis-Chem and Clicks together turn over more than ZAR 85 billion a year, yet much of the country remains under-served outside the major chains. HealthPlus replicates the dispensary-led, front-shop-margin model with a digital-first edge — WhatsApp prescription ordering, app-based loyalty and in-store clinics — rolling out from 3 stores in Phase 1 to 25 by Year 5 and a clear path to 50+ by Year 7, scaling to ZAR 510 million revenue at an 18.8% EBITDA margin, a 24–30% IRR and a 36-month payback.
Plan Contents
This investor-grade business plan is organised into the sections below. Each section is a dedicated page — select any to explore the full detail.
- 1Executive Summary
- 2Industry Analysis
- 3Market Analysis
- 4Products & Services
- 5Operations Plan
- 6Marketing & Customer Acquisition Strategy
- 7Regulatory & Legal Framework
- 8Management Team & Governance
- 9Financial Plan
- 10Risk Analysis & Mitigation
- 11Implementation Roadmap
- 12Exit Strategy
- 13Social Impact & ESG Strategy
- 14Detailed Competitive Positioning
- 15Detailed Unit Economics
- 16Appendices
Disclaimer & Confidentiality Notice
This business plan has been prepared by HealthPlus Pharmacy Group
(Pty) Ltd (the “Company”) for the sole purpose of providing potential
investors and lending institutions with information to evaluate a
prospective investment in or loan to the Company. This document is
strictly confidential and may not be reproduced, distributed, or
disclosed to any third party without the prior written consent of the
Company.
The financial projections and forward-looking statements contained
herein are based on assumptions that the Company believes to be
reasonable as of the date of this document. However, actual results may
differ materially from those projected. Past performance of comparable
businesses is not indicative of future results. The Company makes no
representations or warranties regarding the accuracy or completeness of
the information contained herein.
Prospective investors and lenders should conduct their own
independent due diligence, including but not limited to financial,
legal, regulatory, and tax analysis, before making any investment or
lending decision. This business plan does not constitute an offer to
sell or a solicitation of an offer to buy any securities, nor does it
constitute investment advice.
All financial figures are denominated in South African Rand (ZAR)
unless otherwise stated. Exchange rates and macroeconomic assumptions
are as of April 2026.
Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of HealthPlus Pharmacy Group (Pty) Ltd.